PPBT May 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.13k |
GlobeNewswirePurple Biotech Reports First Quarter 2024 Financial Results
CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the thre
- GlobeNewswire
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled
- GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion a
